Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ DIP and RIP Message Board

Posible D&R $CYTR 2.51 0.00 0.00 337,060 0.84

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 23088
Posted On: 07/12/2016 8:06:31 AM
Avatar
Posted By: fitzkarz
Posible D&R $CYTR 2.51 0.00 0.00 337,060 0.84 0.88

Reason,

CytRx Shares Plunge as Study of Key Cancer Drug Doesn't Meet Primary Endpoint; Second Analysis Planned
14 hours 26 minutes ago - DJNF

By Maria Armental

CytRx Corp. shares dropped sharply as the company said a study of a key cancer drug didn't show evidence of meeting its primary endpoint, and that it plans a second analysis of the data after many patients had to be excluded from analysis due to a partial clinical hold.

The stock plunged 64% to 90 cents in after-hours trading. Through Monday's close, the stock had fallen more than 20% in the past three months.

Los Angeles-based CytRx said the pivotal study of its key drug, aldoxorubicin, as a treatment for soft-tissue sarcoma failed to meet its primary endpoint--showing a significant difference in progression-free survival when compared to the investigator's choice therapy--but showed promising results in objective response rate and disease control rate.

Aldoxorubicin is a modified version of doxorubicin, a widely used anti-cancer drug.

The Food and Drug Administration placed CytRx's aldoxorubicin trial on partial clinical hold in 2014 following a patient's death. The patient was being treated under the company's compassionate use program.

Under a partial hold, the clinical trial continued but no new patients could enroll until the hold was lifted.

CytRx, which has yet to post a profit, said Monday that the interruption didn't allow for sufficient follow-up for the nearly two-thirds of patients enrolled, resulting in the exclusion of nearly half of the patients from the analysis.

Write to Maria Armental at maria.armental@wsj.com

(END) Dow Jones Newswires

July 11, 2016 17:41 ET (21:41 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.


(0)
(0)




I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us